Bionews, Inc.

Spotlight on Pain Management: Our 2024 Rare Patient Survey Findings It's #NationalPainAwarenessMonth, and for many people with rare conditions, managing pain is a daily challenge. Our 2024 Rare Patient Survey uncovered significant gender gaps: ?? ??Women are twice as likely as men to use medication for pain management. ?(Females: 36% vs Males: 18%) Let's raise awareness about the unique experiences faced by those living with chronic pain. Together, we can advocate for better pain management and support. >> If you want more rare disease community insights to elevate your 2025 upfront strategy reach out to Bionews, Inc. at https://lnkd.in/gj9x9zyC #PainAwarenessMonth #ChronicPain #RareDisease #Healthcare #HealthEquity

Medical trauma is a significant challenge many in the rare disease community face. Lara Govendo, a lung transplant recipient and cystic fibrosis patient, sheds light on this often-overlooked reality in her recent column. Read Lara’s column here ?? https://lnkd.in/g25KUtgA Her powerful insights remind us that the emotional and psychological impact of organ transplant among those with cystic fibrosis is just as real as the physical challenges. Bionews, Inc. is committed to elevating patient voices and experiences, ensuring they shape the future of rare disease health and improve outcomes. #Bionews #RareDIsease #CysticFibrosisNewsToday #PateintVoice

?? Celebrating Dedication and Passion! ?? At Bionews, our strength comes from the amazing people who live our mission every day. Today, we’re thrilled to highlight one of our longest-serving team members, Webmaster, Joe Pierce. For 11 years, Joe has been a cornerstone of our company, embodying the passion, drive, and heart that make Bionews, Inc. such a special place to work. “Joe Pierce is always ready to answer the call when needed to keep Bionews running. He's constantly responding to our writers, editorial team, and community with a fix and a smile. His ability to tackle issues with calm efficiency makes him a valued part of the Bionews team." -Jeff LaPointe - SVP - Technology Join us as we celebrate Joe Pierce on this incredible milestone! #Bionews #EmployeeSpotlight #RareDisease #WorkMilestones

Calling all 2025 marketers! Reach engaged rare disease communities (70% Patients/Caregivers) with Bionews. Ready to take your strategy to the next level? Let's talk! Visit: https://lnkd.in/gCMw9MZb As a company with over 50% of our employees living with a rare condition, we understand firsthand the challenges and opportunities within this community. Bionews, Inc. delivers relevant news, personalized storytelling, and strong advertising programs that resonate to drive deeper engagement and measurable ROI for your campaigns. #RareDisease #DigitalHealthMarketing #UpfrontCampaigns

The? Bionews team attended the National Bleeding Disorders Conference in Atlanta ?? Founder and CEO Chris Comish, and EVP of Business Development Ethan Ash,?joined Hemophilia News Today columnists Cazandra Campos-MacDonald and Joe MacDonald at the National Bleeding Disorders Conference in Boston. Caregivers to two sons with severe Hemophilia A (Factor VIII deficiency), this husband and wife team share their unique perspectives as both caregivers and advocates. Lived experiences shape the meaningful conversations we lead around rare disease and provide insight into understanding the unique needs of the patient and caregiver. CTA:? Connect with us to learn how our deep connection and insight into the rare disease community can enhance your 2025 upfront strategy! ???https://lnkd.in/gj9x9zyC Bionews, Inc.'s 50+ rare disease sites, provides trusted information, news, and connections that help to empower the rare disease community, fostering a space where hope thrives. #Bionews #RareDisease #Hemophilia #NBDC #RareCulture

The U.S. Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq), a subcutaneous, or under-the-skin, formulation of Ocrevus (ocrelizumab), for treating adults with multiple sclerosis (MS). The approval covers all the same indications as the original medication, including relapsing forms of MS — namely clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS — as well as primary progressive MS (PPMS). This makes Genentech‘s Ocrevus and Ocrevus Zunovo the only two therapies in the U.S. approved to treat both relapsing MS and PPMS. Read full article here ?? https://lnkd.in/gs9aistJ Multiple Sclerosis News Today, a Bionews, Inc. brand, provides trusted information, news, and connections that help to empower the MS community, fostering a space where hope thrives. #Bionews #FDAApproval #MultipleSclerosis #MSNewsToday #News #DigitalHealth

??Bionews adds Liver Disease News to it’s portfolio of 50+ rare disease communities! ?? https://lnkd.in/gn5GNWWw A dedicated community for those diagnosed or caring for someone with rare liver disease, Liver Disease News is a comprehensive, conditioned-focused hub. Tailored resources for those affected by Liver disease, include: Guidance on daily living: Tools for managing common symptoms and side effects, and in-depth knowledge on how diet and nutrition affect liver disease health. https://lnkd.in/gAfKyT87 Personal stories: Poignant and personal perspectives by patients and caregivers with lived experience. disease. https://lnkd.in/gjQH6BNx News & Latest Research:? Our daily reporting includes news stories detailing the latest research and information on liver disease conditions. https://lnkd.in/gG_TGD3k Don't miss out! Explore the site and connect with us to learn about partnerships and advertising programs! ?? https://lnkd.in/gj9x9zyC #Bionews #LiverDisease #RareDiseaseCommunity #PatientCentric #LiverHealth

Bionews is looking forward to attending the Bleeding Disorders Conference in Atlanta, September 12-14! Let's meet up at the Bleeding Disorders Conference in Atlanta, September 12-14!? Connect with our team, Founder/CEO, Chris Comish, and EVP of Business Development, Ethan Ash, and talk about how Bionews, Inc. can help you create engaging patient-centric content and tailored solutions for people living with rare conditions. ?? Let's chat! #Bionews #RareDisease #BleedingDisordersConference #PharmaMarketing

Our 2024 Rare Disease Patient Insights Survey data reveals that many rare disease patients are overburdened with medications. In fact, 73% of patients are taking 3 or more medications, and 40% are taking 6 or more. This can lead to increased side effects, decreased quality of life, and higher healthcare costs. We need to explore more targeted and effective treatment options to reduce the medication burden for patients with rare diseases. If you want insights to align and elevate your 2025 upfront strategy reach out to Bionews, Inc. at https://lnkd.in/gj9x9zyC #RareDisease #PatientInsights #PharmaMarketing #DigitalMedia #PateintVoice

The Bionews team will be joining industry leaders at Digital Pharma East! Connect with Ethan Ash and Alyssa Crawford to explore how Bionews, Inc. can enhance your 2025 upfront strategy with meaningful insights, patient-centric content, and proven rare-condition focused solutions! #DigitalPharmaEast #PharmaMarketing #Bionews #RareDisease